Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)

BACKGROUND: Androgen receptor (AR) signaling and incomplete inhibition of estrogen signaling may contribute to metastatic breast cancer (MBC) resistance to a nonsteroidal aromatase inhibitor (NSAI; letrozole or anastrozole). We assessed whether combined inhibition of androgen biosynthesis with abira...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Shaughnessy, J., Campone, M., Brain, E., Neven, P., Hayes, D., Bondarenko, I., Griffin, T. W., Martin, J., De Porre, P., Kheoh, T., Yu, M. K., Peng, W., Johnston, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684153/
https://www.ncbi.nlm.nih.gov/pubmed/26504153
http://dx.doi.org/10.1093/annonc/mdv487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684153/
https://www.ncbi.nlm.nih.gov/pubmed/26504153
http://dx.doi.org/10.1093/annonc/mdv487

Ejemplares similares